Compare Bristol-Myers Squibb Co (BMY) vs Harmony Gold Mining Co. (HMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Harmony Gold Mining Co. — how do they compare? Bristol-Myers Squibb Co trades at $63.7 (market cap $129.94B), while Harmony Gold Mining Co. trades at $19.93 (market cap $12.24B). The key difference: Bristol-Myers Squibb Co is far larger — about 10.6× Harmony Gold Mining Co.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | HMY | |
|---|---|---|
Market Cap | $129.94B | $12.24B |
Sector | Health | Basic Materials |
52-Week High | $65.89 | $26.04 |
52-Week Low | $42.60 | $12.61 |
Enterprise Value | $163.92B | $12.58B |
Dividend Yield | 3.96% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
Harmony Gold Mining (HMY) trades at $19.88, down 0.1% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong 2024 results with revenue of $61.38B and net income of $8.59B, supported by a strategic pivot to gold-copper production. Recent news highlights operational progress, including copper profit growth and diversification efforts.
HMY offers value with a P/E of 12.26 and robust profitability margins, but faces risks from gold price volatility and mixed analyst sentiment. The stock's outlook is supported by earnings growth and diversification, though investor caution is warranted due to Fed policy sensitivity and execution risks in expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →
